Peripheral blood progenitor cell reinfusion (PBPC) in patients undergoing high-dose chemotherapy (HDC) for poor prognosis malignancies, has been described as causing possible acute gastrointestinal (nausea, vomiting), allergic (oedema, bronchospasm, anaphylaxis), renal (proteinuria, haematuria) and/or cardiovascular (hypotension, arrhythmia, conduction disturbances, transient ischaemic phenomena) toxicities. To establish the clinical relevance of these observations and the possible relationship with different HDC regimens used, we performed a clinical and instrumental evaluation on 33 patients with advanced breast cancer, nonHodgkin's lymphoma, Hodgkin's disease, relapsed ovarian cancer, Ewing's sarcoma, extragonadal germinal tumour and small cell lung cancer. They underwent at least one reinfusion each for a total of 51 studied procedures. No patient had a previous history of cardiovascular disease or significant intercurrent illness such as diabetes or liver, renal or neurologic impairment. All patients had totally implanted central venous catheters, through which the transplants had been collected and reinfused without technical consequences. To evaluate cardiovascular function, we continuously monitored 12-lead ECGs, with arterial pressure (AP) measurements every 5 min from the beginning of the procedure to 15 min after the reinfusion ended. We did not observe any significant differences between basal and subsequent steps in AP, heart rate, PQ and QTc time, P wave and QRS complex duration or P wave and QRS electrical axes. No patient showed any ST-T tract pathological abnormality, but one patient developed a transient ectopic atrial rhythm, without any haemodynamic disfunction and with spontaneous reversion to sinus rhythm. No patient complained of symptoms of haemodynamic failure. Gastrointestinal side-effects appeared to be strictly related to speed of reinfusion and to the number of packs reinfused, probably reflecting on the amount of dimethylsulphoxide infused. In one patient a 
High-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell (PBPC) rescue have been increasingly used for the treatment of some malignant diseases. This treatment strategy includes PBPC harvested by leukapheresis and cryopreserved for subsequent autografting to restore haemopoiesis after myeloablative cancer therapy.
Reinfusion of cryopreserved haemopoietic progenitors has been shown to be associated with several side-effects possibly related to the presence of dead cells, cell debris (ie free haemoglobin released from lysed red cells) and intracellular cryoprotectant dimethylsulphoxide (DMSO). Reported side-effects include facial flushing, dyspnoea, haemoglobinuria, renal failure, nausea and vomiting, abdominal pain, headache and central nervous system depression. Furthermore, according to the literature, the infusion of cryopreserved grafts can be associated with various cardiovascular effects. Some authors have reported sinus bradycardia (heart rate Ͻ60 b.p.m.) or heart block; 1 others have observed ventricular or supraventricular ectopic beats, supraventricular tachyarrhythmias and QTc prolongation, a phenomenon that is very well known as a significant arrhythmia indicator. 2 Many of these data refer to autologous bone marrow transplantation, with pretreatment with cyclophosphamide and radiotherapy. Only a few series have shown acute cardiovascular effects with infusion of cryopreserved PBPCs [3] [4] [5] [6] despite the growing role of high-dose chemotherapy regimens in the treatment of advanced neoplastic diseases.
Moreover, there are no data on the use of a totally implanted central venous catheter used to collect and/or reinfuse PBSCs in order to better dilute cells and toxic compounds in the blood and prevent acute toxicities.
The purpose of the present study was to evaluate the frequency and severity of potentially serious toxicities associated with PBPC reinfusion in cancer patients treated with HDC.
Patients and methods

Population
Thirty-three patients, 26 females and seven males, treated with high-dose chemotherapy and autologous haemopoietic progenitor cell rescue for poor prognosis malignancies, were analysed in this study (Table 1 ). Thirteen out of 33 patients received anthracycline-containing regimens as primary CT or induction CT. Each patient underwent at least one reinfusion, while 18 patients received repeated reinfusions as a consequence of three cycles of HDC, approximately every 3 weeks, for a total of 51 studied procedures.
Mean age was 39 years, range 22-64 years (41 years, range 28-59 for women and 26 years, range 22-64 for men). Patients had advanced breast cancer (n = 24), intermediate or high-grade non-Hodgkin's lymphoma (n = 2), relapsed or refractory Hodgkin's disease (n = 1), relapsed ovarian cancer (n = 2), Ewing's sarcoma (n = 1), extragonadal germinal tumour (n = 2) and small cell lung cancer (n = 1).
No patient had a previous history of cardiovascular disease and under basal conditions none had clinical evidence of either ischaemic or hypertensive cardiopathy, or echocardiographic evidence of major anatomical or functional valvular dysfunction.
No other significant illnesses such as diabetes, liver, renal or neurologic impairments were present in any patient before the start of therapy. 
Anticancer therapy
The high-dose chemotherapy regimens used were as follows: epirubicin 200 mg/m 2 plus cyclophosphamide 4 g/m 2 (day 0) with PBCPs reinfusion on day 5 for three cycles every 21 days as adjuvant treatment in high-risk breast cancer patients (n = 17); iphosphamide 2.5 g/m 2 plus carboplatin 300 mg/m 2 and etoposide 300 mg/m 2 days 1-4 with PBPC reinfusion on day 6 for three cycles, every 21 days as adjuvant treatment in anthracycline-based primary chemotherapy-resistant breast cancer patients (n = 7), for relapsed or refractory ovarian carcinoma (n = 2), extragonadal germinal tumour (n = 2), Ewing's sarcoma (n = 1), and small cell lung cancer (n = 1); 7, 8 
Collection and reinfusion of PBPC
The blood cell transplant was collected by leukapheresis during mobilisation of PBPC (CD34 + cells) into the peripheral blood, effected by G-CSF (n = 30) or chemotherapy plus G-CSF (n = 3). 11 The content of CD34 + cells was estimated before cryopreservation by direct immunofluorescence flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA) with the phycoerythrin-conjugated HPCA-2 CD34 antibody (Becton Dickinson), as described in detail elsewhere. 15 Before PBPC reinfusion, all patients received i.v. hydration with 5% glucosate solution and albumin 6% (500 ml over 1 h) plus dexamethasone 8 mg, ondansetron 8 mg and maleato clorphenamine 5 mg, all drugs given i.v. over 30 min. At the time of reinfusion, PBPC were thawed in a sterile bath water at 37°C and reinfused without further processing to the patient through a central venous catheter (Port-a-cath; SIMS Deltec, St Paul, MN, USA). After reinfusion all patients received i.v. hydration with 5% glucosate solution 2000 cc/24 h and allopurinol 300 mg × 2 per day for 2 days.
Cryopreservation of PBPC
The blood cell transplant collected by leukapheresis was pelleted in a refrigerated centrifuge, resuspended in a cryoprotectant mixture consisting of 10% DMSO (FarmitaliaCarlo Erba, Milan, Italy) and 90% autologous plasma, and transferred to freezing bags.
The constant final volume of blood cell transplant at cryopreservation ranged from 70 to 100 ml, although the final amount of DMSO infused per pack varied between 7 and 10 ml in total. After sealing, the blood cell transplant-containing bags were rapidly placed into aluminium canisters and immersed in the isopropanol reservoir of a mechanical freezer, programmed for controlled-rate freezing. Cryopreserved blood cell transplants were stored in a −150°C mechanical freezer equipped with a liquid nitrogen rescue system, until reinfusion.
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Cardiological evaluation
Before the start of treatment, all patients underwent complete cardiological evaluation including clinical examination, standard 12-lead ECG (with computerized ECG parameter measurement and vectorcardiography, SIEMENS Megacart, Solna, Sweden) and bidimensional echocardiography (ATL Ultramark, 9HDI, Bothell, WA, USA), for left ventricular ejection fraction (EF) measurement, using Simpson's rule (EF Ͻ50% was an exclusion criterion for the high-dose chemotherapy protocols considered in this study).
During reinfusion we performed continuous ECG, arterial pressure (AP), by standard cuff sphygmomanometer and peripheral oxygen saturation monitoring (SatO 2 ). Clinical and ECG monitoring were performed for 10 min after the end of the reinfusion. Detailed ECG parameters were then determined by independent cardiologists and included heart rate, PQ, QT and Qtc intervals, QRS and P wave axes and duration of any kind of ST-T alterations, VCG alterations and analysis of any rhythm disturbances.
Statistical methods
All results are expressed as mean ± standard error; 95% confidence intervals are also shown. To compare continuous data we used a Student's t-test for paired data, assuming a minimum significance level of P Ͻ 0.05.
Results
Clinical data
PBPC were collected at the time of leukapheresis and reinfused to patients through a totally implanted central venous catheter (Port-a-cath), allowing rapid infusion without technical problems. 16 During each procedure 1.6 ± 1 packs per patient were infused (minimum one/maximum six packs), in a median time of approximately 9 min for each pack. Therefore, the total amount of DMSO infused per patient ranged between 11.2 and 15.7 ml.
Concerning gastrointestinal side-effects, we observed signs of vagal hyperactivity during a few reinfusion procedures, characterised by nausea in 13 patients and vomiting in only four cases. Similar toxicity was observed in one patient with all three reinfusions performed (DM, suffering from ductal carcinoma of the breast treated with a neoadjuvant anthracycline-containing regimen, followed by three HDCT ICE cycles with stem cell support).
Two patients experienced mild abdominal pain of uncertain origin, which rapidly resolved with an antispasmodic. To avoid such symptoms we suggested to all our patients that they postpone food and liquid ingestion on the morning of reinfusion.
One patient experienced a vagal crisis, with hypotension and bradycardia, that became an epileptiform seizure, controlled with a bolus of intravenous diazepam.
Four patients experienced hot flushes and erythema with mild dyspnoea, which spontaneously resolved after the speed of the infusion was reduced. All patients experienced Bone Marrow Transplantation a sore throat and unpleasant taste, due to DMSO elimination, partially resolved by mint-flavoured candies.
All toxicities were reduced by interruption or slowing of the reinfusion and appeared strictly related to the duration of the procedure, particularly when this was shorter than 9 min. Furthermore, 50% of these patients experienced the same problems on infusion of the second or subsequent pack.
Haemodynamic data
Cardiac function, expressed as left ventricular ejection fraction (EF), mean EF 63.6 ± 4.7% and diastolic function, expressed as E/A ratio Ͼ1, were normal in all patients before the start of therapy. No differences were found in these parameters, between patients who had received prior anthracycline-based therapies and those who were receiving first-line adjuvant CT.
During reinfusion, no patient experienced haemodynamic alterations (tachypnoea, dyspnoea, peripheral vasoconstriction, cyanosis, oxygen desaturation) or myocardial ischaemia (chest pain). In 13 patients we observed signs of vagal hyperactivity (nausea = 13, vomit = 4) not associated with haemodynamic alterations.
One patient (TM, female, aged 54) developed a tonicclonic seizure, treated with i.v. diazepam 10 mg, with mild cardiovascular effects (not significant bradycardia, or changes in blood pressure). Peripheral oxygen saturation was steady (98.5% in basal and 97.5% at the end of procedure, NS). We observed a systolic arterial blood-pressure increase from 111.6 ± 1.8 mm Hg to 118.3 ± 2.4 mm Hg after one pack (NS) and to 121.9 ± 2.5 mm Hg after infusion of the last pack where more than one pack was reinfused (NS). Diastolic blood pressure varied from 73.8 ± 1.2 mm Hg to 74.3 ± 1.6 mm Hg after infusion of the first pack and to 75.8 ± 2.6 mm Hg for the final pack (NS) (Figure 1 ). The heart rate was stable: 86. Figure 1 The lack of significant differences in arterial pressure and heart rate trends during first PBPC reinfusion procedure (continuous lines) and further procedures (dotted lines *) demonstrating no additive toxic effects is shown.
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Electrocardiographic parameters
We did not observe significant alterations in atrio-ventricular conduction measured as PQ time (145 ± 4 ms, 139-151 ms 95% CI, at basal and 146 ± 5 ms, 138-156 ms 95% CI at the final stage) or intraventricular conduction (QRS electrical axes 50°± 4°, 43°-57°95% CI, vs 49°± 9°, 28°-64°95% CI, QRS duration 85 ± 1 ms, 83-87 ms 95% CI vs 90 ± 3 ms, 84-94 ms 95% CI). We did not observe any acute alteration in QRS complexes suggestive of paroxysmal ventricular conduction disturbances. P-wave pattern, an indirect but sensitive indicator of atrial function and haemodynamics, did not show significant alterations in shape, duration and axes ( Table 2) .
We also studied QTc duration, often associated with ventricular arrhythmias: no significant differences were found, since these varied between 398 ± 5 ms (388-408 95% CI) at the beginning of the procedure to 382 ± 8 ms (365-399 95% CI) at the end.
Continuous monitoring during all reinfusions and for 10 min after, did not show any significant alterations in ST-T morphology suggestive of transient myocardial ischaemia, myocardial lesions or acute right or left ventricular overload. In one patient (SG, male, aged 34), we observed an ectopic atrial escape rhythm (with sinus-rate reduction), with negative P-wave in D2 and a heart rate of 48 b.p.m. After about 2 min, normal sinus rhythm was spontaneously restored.
In another patient (SB, female, aged 54), we noted sudden appearance of sino-atrial 2:1 block, just after the beginning of nausea and emesis, with spontaneous resolution after 1 min. In both cases there were no symptoms or evidence of haemodynamic disturbances (no significant alterations in arterial blood pressure, normal and unchanged peripheral oxygen saturation). In no patient were reinfusions associated with an increased incidence of isolated or repetitive ventricular or supraventricular ectopic beats or with supraventricular or ventricular tachyarrhythmias or with significant bradycardias.
Finally, in patients who underwent more than one reinfusion (n = 18), we observed no differences in each prereinfusion 12-lead electrocardiogram and no significant dif- Table 2 Haemodynamic and electrocardiographic parameters evaluated during every reinfusion performed in the study. None reached statistical significance
Before
After Difference P reinfusion reinfusion 95% CI mean ± s.e. mean ± s.e.
SBP (mmHg)
116
55 ± 3 5 2± 6 −9/+5 N S SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; QRS dur = duration of QRS; P dur = P wave duration; CI = confidence interval; NS = not significant.
ference in echocardiographic parameters between basal and further evaluations, indicating that toxicities could be acute but not late events.
Discussion
High-dose chemotherapy and PBPC transplantation regimens are increasingly used for the treatment of many malignant diseases associated with a poor prognosis or which are unresponsive with standard chemotherapy protocols. Despite good anticancer results, a higher incidence of side-effects is observed, often a limiting factor for therapy regimens. Some of the well-known toxicities involve the cardiovascular system and are caused by the chemotherapeutic agents themselves.
In the high-dose setting, the therapeutic strategies most commonly implicated in cardiovascular toxicities are highdose radiation therapy, anthracyclines and high-dose cyclophosphamide treatments for lymphomas and a variety of other malignancies. Moreover, there is some evidence in the literature that PBPC reinfusion is directly associated with significant side-effects, mainly cardiovascular. Some authors have reported supraventricular or ventricular arrhythmia or severe bradycardia and heart block, probably caused by DMSO or cells debris contained in the infusate. It is thus important to assess the clinical impact of these potentially fatal, acute and chronic side-effects, because of the increasing role of PBPC rescue after chemotherapy and to attempt to better define the cardiovascular spectrum of contraindications associated with the procedure and the need for safety measures.
In our study we observed no clinically significant cardiovascular side-effects, indicating that it is possible to define a subset of patients in which the procedure is safe and feasible.
Symptoms and signs described in the literature, and occasionally observed in our patients, are a possible expression of transient vagal hyperactivity. Despite these data we did not observe any significant alteration in arterial blood pressure or heart rate both of which were monitored during the whole reinfusion procedure.
No clinically relevant bradyarrhythmia was observed and low atrial escape rhythms and sino-atrial 2:1 blocks did not cause symptoms or haemodynamic alterations and spontaneously reverted to normal sinus rhythm.
Vagal and toxic effects were not evident in intra-atrial, atrio-ventricular or intraventricular conduction, as demonstrated by lack of changes in PQ time, QRS duration and electrical axes.
The absence of any alterations in ST and T wave morphology and polarity mitigates against a relationship between PBPC reinfusion and acute direct myocardial damage, either ischaemic or metabolic. The transient manifestations observed seemed related more to the patient's neurohumoral and psychological status than to myocardial involvement as suggested by their sinus node origin (possibly the most 'neuro-sensitive' region of the heart) and in their short duration and complete reversibility.
Acute gastrointestinal toxicities represent another com-plication related to PBPC reinfusion and is well described in the literature. The insignificant gastrointestinal side-effects observed in our patients may relate on the one hand to the use of systematic premedication with ondansetron 8 mg, methylprednisolone 62.5 mg and maleato clorphenamine 2 mg, administered 30 min before the reinfusion, which can probably prevent symptoms associated with DMSO infusion, and on the other hand to the post-reinfusion hydration and allopurinol administration which may facilitate cell debris elimination by the renal tract. Moreover, it should be stressed that there was a strict relationship between the beginning of the symptoms, the time over which each pack was reinfused and the number of packs reinfused. In fact, nausea, vomiting, abdominal pain, hot flushes and erythema were all reduced by interruption or slowing of the reinfusion, and occurred when duration of the procedure was shorter than 9 min.
In some cases, when the number of packs to be reinfused is more than three, PBPC reinfusion can be performed twice, allowing prevention of symptoms without compromising engraftment.
A specific role must also be reserved for the use of a totally implanted central venous catheter cell collection by leukapheresis procedures and their return to the patient. Use of this device for these purposes has never been reported elsewhere, but it reduces necessity for external manipulation, potentially allowing infection and it is easier to manage for patients and nurses. Moreover, we report no increased risk of catheter thrombosis that could limit its use after transplantation. [16] [17] [18] For these reasons, we consider the use of Port-a-cath a very safe system.
In conclusion, PBPC reinfusion, if managed according to current protocols (including cell cryopreservation, preprocedure medication, reinfusion over an adequate period of time and post-reinfusion hydration) is safe and has a very low cost/efficacy ratio, at least in patients without documented previous cardiac disease. Cardiovascular monitoring is not required routinely, except in those patients with electro-or echocardiographic abnormalities on admission and/or with regard to previous examinations.
